INDBInternet News Database 2.5 Updated 3 min ago · 293 sources Show or hide images Light or dark

Results for “Cel Genesis”

Entertainment
1 source

Who is covering this

Exclaim Ca All ArticlesNo political lean
Truth score 34
No rated outlets yet
Exclaim Ca All ArticlesNo political lean

The Body Tap Cel Genesis for 2027 North American Tour

Experimental metallers the Body and Cel Genesis are teaming up for a joint North American tour in support of their collaborative album

Lean: No political lean Fact-focusedCountry: CanadaFunding: CorporateOwner: Independent
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
Canada100%
Media ownership
Independent100%
Avg reliability-
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 34 (Weakly supported) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: Not rated Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Analyze: Compare coverage
Like
Health
1 source

Who is covering this

MedscapeCenter
Truth score 38
Centre 100%100%
MedscapeCenter

Liso-Cel in 3L Follicular Lymphoma: Has the Debate Ended?

A recent commentary says longer follow-up of TRANSCEND follicular lymphoma makes liso-cel the best third-line option for patients who can get it. But caveats remain.

Lean: Center Fact-focusedFactuality: Mostly factualCountry: United StatesFunding: CorporateOwner: Independent
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United States100%
Media ownership
Independent100%
Avg reliability65
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 38 (Weakly supported) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 65 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 6 Amplification: 0

How we score

Analyze: Compare coverage
Like
Health
2 sources

Who is covering this

MedscapeCenterMedpagetodayCenter
Truth score 48
Centre 100%100%
MedpagetodayCenter

After CAR-T Failure in Diffuse Large B-Cell Lymphoma, What Comes Next?

(MedPage Today) -- CD19-targeted chimeric antigen receptor (CAR) T-cells have emerged as a second- and later-line treatment strategy for patients with diffuse large B-cell lymphoma (DLBCL), with three FDA-approved products. "Across CAR T-cell...

Lean: Center Fact-focusedFactuality: Mostly factualCountry: United StatesFunding: CorporateOwner: Independent
  • Medscape Zamto-Cel Improves EFS in Large B-Cell Lymphoma

    A phase 2 trial compares dual-targeted CAR T-cell therapy with R-GemOx as second-line treatment for patients with relapsed or refractory large B-cell lymphoma who are ineligible for transplantation.

    Lean: Center Fact-focusedFactuality: Mostly factualCountry: United StatesFunding: CorporateOwner: Independent
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United States100%
Media ownership
Independent100%
Avg reliability65
Low-credibility share0%
Fact / opinion2/0
State media0%
More analysis
Truth score: 48 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 2 Reliability: 65 Bias severity: 0 Risk: 0Sentiment: 100Sensationalism: 3 Amplification: 0

How we score

Analyze: Misinfo Radar
Like